The company said it will soon ask health officials in the U.S. and around the world to authorize the pill’s use.
Courthouse News Service's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Names this update
Merck says Covid-19 pill cuts risk of death, hospitalization
Headline from Courthouse News Service ·
Newest
Merck pill seen as 'huge advance,' raises hope of preventing COVID-19 deaths
WASHINGTON (AP) — Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon
Pharmaceutical company Merck says its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus.
Pharmaceutical company Merck on Friday said it will seek an emergency authorization for their oral antiviral COVID-19 treatment after the medicine was shown to reduce the risk of hospitalization by 50 percent during clinical trials.
In a late-stage clinical trial, a new antiviral pill halved the chance that patients diagnosed with COVID-19 would end up in the hospital or die from the disease, the drugmaker Merck announced Friday (Oct. 1).
A global trial of the pill enrolled 775 people with mild or moderate covid-19. Participants had at least one risk factor for severe covid-19, such as obesity or advanced age. They had to start the dru...
WASHINGTON — Pharmaceutical company Merck says its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus.
Company says molnupiravir cut hospitalizations and deaths by half in people recently infected with the virus and it will soon ask authorities to approve the pill's use.
How effective was the drug in trials? So effective that an independent panel looked at some preliminary data and told Merck there was no reason to see those trials through to completion. The pill was...
Pharmaceutical company Merck will apply for emergency use authorization for a pill that may be the first to treat COVID-19, according to experiment results released by the company on Friday.
Pharmaceutical giant Merck announced promising results from a study of a new antiviral drug. Molnupiravir reduced COVID hospitalizations or death by 50% in a trial involving 775 volunteers.
By Travis Caldwell, CNN A pill has cut the risk of hospitalization or death from Covid-19 by half in a study, Merck and Ridgeback Therapeutic said Friday. It would become the first oral antiviral for Covid-19 if approved by the US Food and Drug Administration for emergency use authorization.
(HealthDay)—Pharmaceutical giant Merck & Co. said Friday that it will seek federal approval for emergency use of its new antiviral pill molnupiravir, after a clinical trial showed the drug halved the risk of hospitalization or death when given to high-risk people shortly after infection with COVID-1…
Showing the first 25 of 47 headlines. ·
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Merck says Covid-19 pill cuts risk of death, hospitalization | Since Then
